



# The Richard Doll Seminars in Public Health and Epidemiology

## Professor Hans Lilja

*Nuffield Department of Surgical Sciences  
University of Oxford*

\*\*\*\*\*

“Long-term risk of lethal prostate cancer by prostate-specific antigen (PSA) and related markers in blood at age 40 to 60”

\*\*\*\*\*

**Tuesday 12<sup>th</sup> Nov 2013**  
**1-2 pm**

**Lecture Theatre, Richard Doll Bldg, Old Road Campus**

<http://www.ceu.ox.ac.uk/seminars>


Follow us  [@rdseminars](https://twitter.com/rdseminars)

All welcome



### **Hans Lilja MD PhD**

Professor of Clinical Biochemistry, University of Oxford  
Member and Attending Clinical Chemist,  
Memorial Sloan-Kettering Cancer Center, New York



**Dr. Hans Lilja** trained at *Lund University in Malmö, Sweden* (MD in 1978, PhD in 1985) and was appointed Professor of Clinical Chemistry in 1999. In 2003, Dr. Lilja moved to *Memorial Sloan-Kettering Cancer Center* in New York where he was appointed Member and Attending Clinical Chemist in the Departments of Laboratory Medicine, Surgery (Urology) and Medicine (GU-Oncology). In 2012, Dr. Lilja was appointed as Professor of Clinical Biochemistry at the Nuffield Department of Surgical Sciences at *University of Oxford*. He is also Visiting Professor at *Lund University* and Finland Distinguished Professor at *University of Tampere*.

Dr. Lilja was first to characterize the enzymatic action and physiologic substrates to prostate-specific antigen (PSA) and subsequently discovered that PSA occurs in blood either bound to antiproteases or unbound, and that the free-to-total PSA ratio is an independent risk factor for prostate cancer, leading to a widespread implementation of the free PSA assay as a novel cancer biomarker. His research continues to focus on the relationship between biomarker function and the pathophysiology of the male accessory sex glands, biomarker discovery and assays, and clinical validation of biomarkers in population-based cohorts with long-term follow-up.

Dr. Lilja has 250+ peer-reviewed scientific reports and 60+ review articles, and is an editorial board member of several journals. He also holds 10+ patents issued in Europe, the US and Japan. He received the **Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics** from the American Association for Clinical Chemistry in 2012 and the **Abbott Award from the International Society of Oncology and BioMarkers**.